RFPT02.2- “How do you live the best life you can with this pain?”: A qualitative study of the challenges of living with CF and pain in the modulator era
W04.3- Elexacaftor/tezacaftor/ivacaftor concentrations are similar between transplanted and non-transplanted people with CF
Location: 253 A-C
Speaker: Jennifer Guimbellot – Arkansas Children's Hospital/Arkansas Children's Research Institute
CLIN
Thursday, Sep 26th
10:15 AM – 12:15 PM ET
W04.4- Impact of Elexacaftor-Tezacaftor-Ivacaftor on the predicted 3-year risk of death or lung transplantation for individuals with advanced CF lung disease.
W07.2- The Impact of CFTR Modulator Therapy on Acute Pancreatitis Frequency in Children with Acute Recurrent or Chronic Pancreatitis: A Report from INSPPIRE-2
W07.3- Intestinal complications in cystic fibrosis: Insights from F508del-Cftr mice on mucin dynamics and altered cellular functions
Location: 207
Speaker: Hailey Dodson – University of North Carolina at Chapel Hill
CLIN
Thursday, Sep 26th
10:15 AM – 12:15 PM ET
W07.4- Frequency of hepatobiliary abnormalities in young children with CF before and after 6 months of elexacaftor/tezacaftor/ivacaftor: Results from the BEGIN Study
W07.5- Elexacaftor, tezacaftor and ivacaftor (ETI) do not improve indices of hepatic fibrosis, liver stiffness or hepatic steatosis after 3 years, interim results of the PROMISE study.
W11.3- Remotely addressing social risk factors (ELICIT) in cystic fibrosis: Design and implementation of a multicenter screening and intervention QI project
W13.4- The Effect of Omnipod 5 (OP5) Hybrid Closed Loop (HCL) Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes (CFRD)
RFPT04.2- A quality improvement initiative improves timeliness of sweat test completion after referral for positive newborn screen at a large single center
RFPT04.7- Our patients asked and we listened: Increasing efficiency and decreasing total time of cystic fibrosis quarterly visits through quality improvement
TPS03.3- The Stockholm Elexacaftor/Tezacaftor/Ivacaftor Task Force Study: Cohort description and identification of subgroups
Location: Theater A (Exhibit & Poster Hall)
Speaker: Terezia Pincikova, MD, PhD (she/her/hers) – Stockholm CF Center, Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
CLIN
Thursday, Sep 26th
2:30 PM – 4:00 PM ET
TPS03.4- Plasma proteomics identifies changes in disease-associated pathways in subjects with CF bronchiectasis following Elexacaftor/Tezacaftor/Ivacaftor Initiation
TPS03.7- Detection of Nontuberculous Mycobacteria Disease Using Volatile Biomarkers
Location: Theater A (Exhibit & Poster Hall)
Speaker: Antao Gao, MS – University of British Columbia
CLIN
Thursday, Sep 26th
2:30 PM – 4:00 PM ET
TPS03.8- Detection of Nontuberculous Mycobacteria Abscessus and Phage Treatment Response Using Volatile Biomarkers
Location: Theater A (Exhibit & Poster Hall)
Speaker: Antao Gao, MS – University of British Columbia
CLIN
Thursday, Sep 26th
2:30 PM – 4:00 PM ET
TPS03.9- Longitudinal profiles of human breath reveal potential biomarkers for detecting and monitoring infections in cystic fibrosis during ivacaftor and antibiotic therapies
TPS03.10- Development of a co-culture model for secondary screening of candidate anti-microbial compounds targeting persistent lung infections in cystic fibrosis.
RFPT07.2- Evaluation of Pulmonary Ventilation and Perfusion in Cystic Fibrosis Lung Disease using Functional Proton and Hyperpolarized Xe Magnetic Resonance Imaging
RFPT07.3- Establishing a magnitude-independent minimum clinically important difference of hyperpolarized xenon-129 magnetic resonance ventilation imaging
RFPT07.5- Early Cystic Fibrosis Lung Disease Progression by Multiple-Breath Washout and Chest Magnetic Resonance Imaging
Location: Theater B (Exhibit & Poster Hall)
Speaker: Eva Steinke, MD (she/her/hers) – Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Germany
APPTTCLIN
Friday, Sep 27th
9:00 AM – 9:50 AM ET
RFPT07.6- Longitudinal Evaluation of the Responsiveness of Hyperpolarized 129Xe Multiple-Breath Washout MRI to Elexacaftor/Tezacaftor/Ivacaftor Treatment in Pediatric Cystic Fibrosis
RFPT07.7- Elexacaftor/tezacaftor/ivacaftor therapy improves lung clearance Index and magnetic resonance imaging scores in children with cystic fibrosis and one or two F508del alleles
W19.3- Remote social needs screening and intervention: Early results and lessons learned from implementation of the ELICIT study at two large pediatric CF centers
W22.1- Adherence to Elexacaftor/Tezacaftor/Ivacaftor and clinical outcomes in People with Cystic Fibrosis (CF) – the RECOVER Study
Location: 258 A-C
Speaker: Paul McNally – RCSI University of Medicine and Health Sciences
CLIN
Friday, Sep 27th
10:15 AM – 12:15 PM ET
W22.2- Effect of Elexacaftor-Tezacaftor-Ivacaftor on Long-Term Lung Function and BMI Trajectories
Location: 258 A-C
Speaker: George M. Solomon, MD – University of Alabama at Birmingham, Birmingham, AL USA
CLIN
Friday, Sep 27th
10:15 AM – 12:15 PM ET
W22.3- Liver disease outcomes in people with CF after two years of Elexacaftor/Tezacaftor/Ivacaftor – Results from the RECOVER trial
Location: 258 A-C
Speaker: Paul McNally – RCSI University of Medicine and Health Sciences
CLIN
Friday, Sep 27th
10:15 AM – 12:15 PM ET
W22.4- Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis. Data from the French observational pediatric study MODUL-CF
W25.1- Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ Triple) in Adolescents and Adults with CF: Results from Two Randomized, Active-Controlled Phase 3 Trials
W26.2- Improvement in abdominal symptoms (CFAbd-Score) and gut inflammation over 12 months of treatment with Elexacaftor/Tezacaftor/Ivacaftor in children with CF aged 6-11– results from the RECOVER study
W36.1- Significant impact of menopause transition in UK females with cystic fibrosis (fwCF): a large-centre study in the highly effective modulator therapy (HEMT) era
W36.2- Longitudinal changes in bone mineral density in adolescents and adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor – results from the PROMISE study